PainChek raises A$5.5M via convertible notes for US market expansion
What's the deal? PainChekDealroom has a profile for this one. Try Dealroom →, an ASX-listed digital health company, has entered binding agreements to raise $5.5 million through unsecured convertible notes. The funds will support working capital and the company's sales push across North America.
The round was backed entirely by existing professional and sophisticated investors. The convertible notes carry a 12-month maturity, a fixed conversion price of $0.195 per share, and monthly cash interest payments. Noteholders can convert at any time before maturity.
If investors convert and shareholders approve, they'll also receive one free option for every two shares issued.
Why now? The raise follows PainChek's landmark agreement with SabraDealroom has a profile for this one. Try Dealroom →, covering 350 US aged-care facilities. It has also gained access to remote therapeutic monitoring reimbursement pathways — a key revenue unlock in the US healthcare system.
CEO Philip Daffas said the funds provide "the essential financial runway to accelerate the company's North American growth initiatives."
What could go wrong? The conversion price of $0.195 sits well above PainChek's share price of $0.14 at the time of reporting — a 39% premium. If the stock doesn't climb, noteholders may choose not to convert, leaving the company with debt to repay at maturity.
Convertible notes also carry dilution risk for existing shareholders, particularly if the attached options are exercised.
The signal: Classified as an early-growth company by Dealroom, PainChek's decision to use convertible notes rather than a traditional equity raise underscores the financing constraints facing small-cap health tech firms expanding into the US market. The 350-facility Sabra agreement offers a meaningful distribution footprint, but with a share price sitting 28% below the conversion price, the structure effectively asks existing backers to fund a growth thesis that the public market hasn't yet priced in.
Read more: grafa.com
